Press releases
- Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index
- Lineage to Present at 2024 BIO International Convention
- Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
- Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
- Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
- Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
- Lineage Announces Changes to Board of Directors
More ▼
Key statistics
On Monday, Lineage Cell Therapeutics Inc (BT3:DUS) closed at 0.90, 13.21% above the 52 week low of 0.795 set on Jul 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.89 |
---|---|
High | 0.905 |
Low | 0.89 |
Bid | -- |
Offer | -- |
Previous close | 0.90 |
Average volume | 0.00 |
---|---|
Shares outstanding | 188.82m |
Free float | 188.00m |
P/E (TTM) | -- |
Market cap | 200.15m USD |
EPS (TTM) | -0.1344 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 18:31 BST.
More ▼